VOXEL-BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER’S DISEASE CONTINUUM

Abstract

abnormal amyloid biomarkers are possible, with either CSF or PET becoming abnormal first (Figure 2). The hypothesis whereby CSF represents a dynamic measure of ongoing amyloid accumulation may only partially account for biomarkers mismatches. Since amyloid PET tracers primarily bind to dense-core fibrillary plaques and not to protofibrils or oligomers, biological factors underlying individual differences in the conformation of amyloid aggregates may partly explain the observed discordance, advocating for the need for diverse biomarkers for patient stratification.